Login
$HRMY
$32.96 -$0.80 (2.37%) Live

$HRMY SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

30 Oct 2026 8-K/A: Departure/Election of Directors or Officers; Compensation

THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 29, 2026, and effective as of January 1, 2027 (the “Effective Date”), is made by and between Harmony Biosciences Management, Inc., a Delaware...

27 Oct 2026 SCHEDULE 13G/A
13 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027.

18 Sep 2026 Form 4: Budur Kumar, CHIEF MEDICAL OFFICER

Received 1,800 shares by exercise or conversion ($54.9K) · Sold 1,800 shares ($77.4K) · Received 800 shares by exercise or conversion ($24.4K) · 3 more

18 Sep 2026 144
17 Sep 2026 144
16 Sep 2026 144
09 Sep 2026 Form 4: Budur Kumar, CHIEF MEDICAL OFFICER

Sold 5,500 shares ($231K) · Sold 28,454 shares ($1.22M) · Received 22,954 shares by exercise or conversion ($700K)

08 Sep 2026 144
04 Sep 2026 144
07 Aug 2026 144
04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

31 Jul 2026 SCHEDULE 13G
28 Jul 2026 SCHEDULE 13G/A
22 Jul 2026 Form 3: Mollichella Stephen M., INT PRINCIAL FINANCIAL OFFICER

Holds 2,506 shares of Common Stock

16 Jul 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

This Separation Agreement (this “Agreement”) is entered into by and between Glenn Reicin (“Executive”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together the “Company”), effective as of July 16, 202...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support